Scott Fidel

Curious around how you see the continuity around those 5 growth pillars? Or do you see potentially making

do you feel like at this point now, you've largely fully aligned your PBM model with how the regulators, with how the policymakers, have been really pushing the industry to adapt to

Can you walk us through maybe some of the key building blocks that are the inputs into that? And just thinking about some of the most impactful dynamics

Do you think that the persistency of the clients may benefit from the fact that others in the market will also be needing to take similar pricing actions

how much of that dynamic have you been seeing? Are you seeing some convergence between the two around those spending trends

walk us through the book in terms of some of the dynamics, Drew, around the LIS versus the non-LIS populations

whether you'd be comfortable maybe just giving us a bit more of a sort of fine-tuning on your expectations for operating cash flow in 2025

If you could maybe give us an update on how medical cost trends are progressing there

giving us an update on the risk-based management programs that you've been deploying in Carelon services

just sort of touch on the M&A priorities in terms of, one, just appetite for doing transactions this year just given the dynamic backdrop

just I know on D-SNP that that's an area you want to continue to focus on moving forward. And maybe give us some thoughts on how you see that positioned for '26

I was hoping maybe, Mark, if you could also just elaborate on Health Benefits and whether those margin targets are still intact for '27 or have evolved

Were they relatively consistent or would the exchange sort of disruption, did you see any sort of movement around the different payer

talk about what you saw with acuity and case mix in the quarter

Curious if you could talk a bit about your expectations for growth in terms of specialties and procedures in 2026

I was hoping if you could maybe drill a bit more into the Medicare volumes in the quarter and break those down for us between Medicare Advantage and then fee-for-service

if you've done any type of preliminary analysis around Trump's tariff proposals and if you think there could be any net effect or economic impact from that

how you're seeing sort of those trends on the new members of particular maybe playing out between HMO and PPO?

Can you give us some detail into relative to the 25% overall MA growth that breaks down in terms of PPO?

from a product mix perspective, how you're seeing new sales tracking between PPO, HMO and then, I guess, maybe D-SNP products?

Was hoping to get maybe a little more visibility or insight just into the Medicaid margin trajectory and sort of how that's flowing from 2024 into 2025

the the net supplemental payments 2024, the the $1.016 billion. Just what the split is between acute and b h

it does look like the MAA piece is is a driver of that, but maybe just sort of walk us through from a product perspective

interested if you could just provide us with the breakdown of the 1.3 million to 1.4 million commercial risk lives

Can you also just update us on sort of the dividend and what your view is on the dividend

if you would help us maybe in thinking about any comments on EPS seasonality that may be different in 2025 relative to '24